Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P2.08 - Poster Session 2 - Radiotherapy
- Type: Poster Session
- Track: Radiation Oncology + Radiotherapy
- Presentations: 27
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.08-001 - Start of phase transition "norm---early lung cancer" significantly depended on blood immune cell circuit
09:30 - 09:30 | Author(s): O. Kshivets
- Abstract
Loading... -
+
P2.08-002 - Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A publication-based meta-analysis
09:30 - 09:30 | Author(s): C. Billiet
- Abstract
Loading... -
+
P2.08-003 - Involved-Field Radiotherapy versus Elective Nodal Irradiation in Combination with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study
09:30 - 09:30 | Author(s): H.L. Ma
- Abstract
Loading... -
+
P2.08-004 - Impact of medical co-morbidities on survival in patients treated with stereotactic body radiotherapy for early stage non-small cell lung cancer
09:30 - 09:30 | Author(s): M.L. Yap
- Abstract
Loading... -
+
P2.08-005 - 4D-PET/CT-based adaptive dose escalated radiotherapy (RT) in locally advanced non-small cell lung cancer (LA-NSCLC)
09:30 - 09:30 | Author(s): M.L. Yap
- Abstract
Loading... -
+
P2.08-006 - Efficacy of Single Dose 8-Gy Palliative Chest Irradiation in Pain Palliation of Patients with Locoregionally Recurrent Stage IV Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P2.08-007 - Impact Surgical Resection and Radiosurgery Directed To Brain Metastasis on Survival Outcomes in Non-Small Cell Lung Cancer Patients with Synchronous Single Brain Metastasis
09:30 - 09:30 | Author(s): C. Parlak
- Abstract
Loading... -
+
P2.08-008 - A prospective study to determine inter-observer variability of Gross Tumor Volume with FDG-PET/CT compared to CT alone in Stage III Non-Small Cell Lung Cancer using Three-dimensional Analysis.
09:30 - 09:30 | Author(s): D.J. Peterson
- Abstract
Loading... -
+
P2.08-009 - Stereotactic Ablative Body Radiotherapy (SABR) Outcomes for Primary and Metastatic Non-Small Cell Lung Cancer (NSCLC) Pulmonary Tumours
09:30 - 09:30 | Author(s): I. Thibault
- Abstract
Loading... -
+
P2.08-010 - Outcome of Epidermal Growth Factor Receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) patients (p) with Brain metastases (BM) in a single institution: Value of the lung-GPA classification
09:30 - 09:30 | Author(s): M. Jove
- Abstract
Loading... -
+
P2.08-011 - Utility of MRI in Lung Cancer radiotherapy: a Literature Review
09:30 - 09:30 | Author(s): S. Kumar
- Abstract
Loading... -
+
P2.08-012 - Treatment of Multiple Primary Lung Cancers (MPLC) with stereotactic ablative radiotherapy (SABR)
09:30 - 09:30 | Author(s): G.H. Griffioen
- Abstract
Loading... -
+
P2.08-013 - Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium?
09:30 - 09:30 | Author(s): Y. Lievens
- Abstract
Loading... -
+
P2.08-014 - The influence of age on the outcome of concurrent chemo-radiotherapy in locally advanced NSCLC
09:30 - 09:30 | Author(s): O. Hansen
- Abstract
Loading... -
+
P2.08-015 - Stereotactic body radiotherapy with Helical tomotherapy for lung tumor: Treatment outcome and feasibility
09:30 - 09:30 | Author(s): S.H. Kim
- Abstract
Loading... -
+
P2.08-016 - Use of palliative radiotherapy in lung cancer during the last weeks of the life.
09:30 - 09:30 | Author(s): A. Tursunovic
- Abstract
Loading... -
+
P2.08-017 - Increasing expected local control for locally advanced NSCLC patients with inhomogeneous dose-escalation
09:30 - 09:30 | Author(s): T.B. Nielsen
- Abstract
Loading... -
+
P2.08-018 - Interobserver Variability in Target Volume Delineations in Postoperative Radiotherapy for NSCLC.
09:30 - 09:30 | Author(s): T. Schytte
- Abstract
Loading... -
+
P2.08-019 - Palliative radiation during pemetrexed plus cisplatin first-line treatment or pemetrexed continuation maintenance treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): A report of patient safety in the PARAMOUNT trial
09:30 - 09:30 | Author(s): F. De Marinis
- Abstract
Loading... -
+
P2.08-020 - Prognositc parameters for local and regional control in locally advanced NSCLC patients treated with concurrent chemo-radiotherapy
09:30 - 09:30 | Author(s): C. Chen
- Abstract
Loading... -
+
P2.08-021 - Comparison of Two Radiotherapy Planning Techniques for Stage IIIA and IIIB NSCLC: Volumetric Modulated Arc Therapy (VMAT) vs 3D Conformal Radiotherapy (3DCRT)
09:30 - 09:30 | Author(s): K. Small
- Abstract
Loading... -
+
P2.08-022 - Non-Small Cell Lung Cancer (NSCLC): Changes in volume during radiotherapy and potential adaptive radiotherapy planning
09:30 - 09:30 | Author(s): G.K. Ho
- Abstract
Loading... -
+
P2.08-023 - Intensity-modulated radiation therapy for inoperable non-small cell lung cancer: Experience at Samsung Medical Center
09:30 - 09:30 | Author(s): J.M. Noh
- Abstract
Loading... -
+
P2.08-024 - A new dose constraint reduce the incidence and severity of radiation-induced pneumonitis in locally advanced NSCLC treated with Intensity-Modulated Radiotherapy
09:30 - 09:30 | Author(s): A.A. Khalil
- Abstract
Loading... -
+
P2.08-025 - A study of respiratory-induced tumour motion based on anatomical lung location using 4DCT in lung cancer patients
09:30 - 09:30 | Author(s): K.V.S. Tan
- Abstract
Loading... -
+
P2.08-026 - Prospective Study of Stage I Non-Small-Cell Lung Cancer Treated with Hypofractionated SIB IMRT
09:30 - 09:30 | Author(s): W. Zhang
- Abstract
Loading... -
+
P2.08-027 - Atlas segmentation for lung stereotactic ablative radiotherapy
09:30 - 09:30 | Author(s): J. Barber
- Abstract
Loading...
-
+
P2.09 - Poster Session 2 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.09-001 - Phase II study of concurrent chemo-radiotherapy (CRT) with weekly cisplatinum plus oral vinorelbine in fit elderly patients with nonresectable locally advanced non-small-cell lung cancer (NSCLC) assessed by Standardized Geriatric Assessment (RACCOSA, GFPC 08-06 study): interim analysis.
09:30 - 09:30 | Author(s): C. Locher
- Abstract
Loading... -
+
P2.09-002 - Prognostic impact of conventional and modified measurement of mediastinal lymph node involvement in the outcome of patients with resected locally advanced non-small cell lung cancers previously treated with inductive chemo or chemoradiation
09:30 - 09:30 | Author(s): D. Marquez-Medina
- Abstract
Loading... -
+
P2.09-003 - Concurrent Chemoradiation (CChRT) for stage III Non-Small Cell Lung Cancer (NSCLC): a phase II study from the Galician Lung Cancer Group.
09:30 - 09:30 | Author(s): J. Casal
- Abstract
Loading... -
+
P2.09-004 - Phase II study of sequential versus concurrent chemotherapy and radiotherapy in poor risk patients with inoperable stage III non-small cell lung cancer (NSCLC): final results of the Spanish Lung Cancer Group 00-05 study
09:30 - 09:30 | Author(s): F. Cardenal
- Abstract
Loading... -
+
P2.09-005 - Cisplatin, S-1 and concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group 0501
09:30 - 09:30 | Author(s): H. Ueoka
- Abstract
Loading... -
+
P2.09-006 - Long-term results of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Naito
- Abstract
Loading... -
+
P2.09-007 - Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel and cisplatin/etoposide in stage III non-small cell lung cancer
09:30 - 09:30 | Author(s): M.S. Liew
- Abstract
Loading... -
+
P2.09-008 - Concurrent chemoradiotherapy (cCTRT) for locally advanced Non Small Cell Lung Cancer (NSCLC) followed by consolidation Pemetrexed: a phase II study
09:30 - 09:30 | Author(s): C. Faivre-Finn
- Abstract
Loading... -
+
P2.09-009 - Impact of Change in Hemoglobin Levels During Treatment on Prognosis in Non-anemic Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P2.09-010 - Variation in the Uptake of the Combined Modality Practice Guideline for Surgically Unresectable Stage III NSCLC in Ontario
09:30 - 09:30 | Author(s): W. Evans
- Abstract
Loading... -
+
P2.09-011 - Tumor arising from lower lobes is a poor prognostic factor in non-small cell lung cancer patients with N2 disease treated with induction chemoradiotherapy
09:30 - 09:30 | Author(s): K. Suzawa
- Abstract
Loading... -
+
P2.09-012 - Prognostic Value of Tumor Survivin Expression in Stage III Non-small Cell Lung Cancer Patients Treated with Platinum-based Chemoradiation Therapy Followed by Surgery
09:30 - 09:30 | Author(s): H.R. Kim
- Abstract
Loading... -
+
P2.09-013 - Treatment outcome in 136 patients (pts) with inoperable or irresectable non-small cell lung cancer (NSCLC), staged with PET-scan, treated with concurrent (cc) low-dose daily cisplatin and high-dose radiotherapy
09:30 - 09:30 | Author(s): E. Dieleman
- Abstract
Loading... -
+
P2.09-014 - Concomitant Chemoradiotherapy Using Docetaxel and Cisplatin for Unresectable Stage III Lung Squamous Cell Carcinoma
09:30 - 09:30 | Author(s): Y. Xu
- Abstract
Loading... -
+
P2.09-015 - Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small cell lung cancer: A propensity score matching analysis
09:30 - 09:30 | Author(s): H.J. Kim
- Abstract
Loading... -
+
P2.09-016 - A feasibility study of neoadjuvant chemotherapy with cisplatin, pemetrexed and bevacizumab followed by surgery for nonsquamous non-small cell lung cancer
09:30 - 09:30 | Author(s): K. Takamochi
- Abstract
Loading... -
+
P2.09-017 - Phase III study of concurrent cisplatin with pemtrexed versus vinorelbine and LCAHRT for unresectable stage III NSCLC
09:30 - 09:30 | Author(s): B. Li
- Abstract
Loading... -
+
P2.09-018 - Incorporating erlotinib into induction chemotherapy followed by concurrent chemoradiation of unresectable stage III non-small cell lung cancer according to EGFR mutation status: preliminary result of a randomized phase II study
09:30 - 09:30 | Author(s): Y. Lee
- Abstract
Loading...
-
+
P2.10 - Poster Session 2 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.10-001 - Modelling of cost effectiveness in advance NSCLC of a four arm treatment sequence with biomarkers. Using a Filemaker app
09:30 - 09:30 | Author(s): J.A. Davidson
- Abstract
Loading... -
+
P2.10-002 - Phase I dose escalation study of pemetrexed and carboplatin in chemothearpy-naive elderly patients with advanced non-squamous non-small cell lung cancer.
09:30 - 09:30 | Author(s): H. Takeoka
- Abstract
Loading... -
+
P2.10-003 - A multicenter, proof-of-concept study of short-term supplementation of folic acid and vitamin B12 prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.
09:30 - 09:30 | Author(s): Y. Takagi
- Abstract
Loading... -
+
P2.10-004 - Addition of bevacuzimab (BEV) to pemetrexed (PEM) plus cisplatin (CIS) induction and PEM maintenance therapy in 1st line setting for treatment of advanced nonsquamous non small cell lung cancer (NS-NSCLC) - final results and safety update from a phase 2 study
09:30 - 09:30 | Author(s): G. Hillerdal
- Abstract
Loading... -
+
P2.10-005 - Erlotinib (E) can be safely administered in pts > 80 years old
09:30 - 09:30 | Author(s): I. Gkiozos
- Abstract
Loading... -
+
P2.10-006 - Prognostic value of the Ratio of Positron Emission Uptake to Primary Tumor Size in advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Song
- Abstract
Loading... -
+
P2.10-007 - Phase II trial of Pemetrexed and Carboplatin followed by Pemetrexed continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): K. Nishino
- Abstract
Loading... -
+
P2.10-008 - Establishing the Optimal Nebulization system for Paclitaxel, Docetaxel, Cisplatin, Carboplatin and Gemcitabine; Back to Drawing the Residual Cup.
09:30 - 09:30 | Author(s): K. Zarogoulidis
- Abstract
Loading... -
+
P2.10-009 - Intrinsic and acquired resistance patterns in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
09:30 - 09:30 | Author(s): D.J. Stewart
- Abstract
Loading... -
+
P2.10-010 - Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: results of a prospective study in nonrandomized and unselected population of 396 patient
09:30 - 09:30 | Author(s): J. Skrickova
- Abstract
Loading... -
+
P2.10-011 - Pemetrexed in combination with cisplatin in the first-line treatment of non-squamous NSCLC: Czech experience with 233 patients
09:30 - 09:30 | Author(s): J. Skrickova
- Abstract
Loading... -
+
P2.10-012 - Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Igawa
- Abstract
Loading... -
+
P2.10-013 - Randomized non comparative multicenter phase II study of sequential erlotinib with docetaxel versus docetaxel alone in patients with non small cell lung cancer (NSCLC) after failure of first line chemotherapy (TARSEQ): a GFPC 10.02 study.
09:30 - 09:30 | Author(s): J.B. Auliac
- Abstract
Loading... -
+
P2.10-014 - A phase II study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous (Non-Sq) non-small-cell lung cancer (NSCLC) harboring Mutations of Epidermal Growth Factor Receptor (EGFR) gene after failing First-line EGFR-Tyrosine Kinase Inhibitors (TKIs) Hanshin Oncology Group 0109
09:30 - 09:30 | Author(s): Y. Namba
- Abstract
Loading... -
+
P2.10-015 - Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non small cell lung cancer, particularly in the elderly: A ten year retrospective population-based review
09:30 - 09:30 | Author(s): N. Murray
- Abstract
Loading... -
+
P2.10-016 - Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small-cell lung cancer harboring an epidermal growth factor receptor activating mutation
09:30 - 09:30 | Author(s): S. Kanda
- Abstract
Loading... -
+
P2.10-017 - Efficacy of Pemetrexed in advanced non-small cell lung cancer with asymptomatic brain metastases
09:30 - 09:30 | Author(s): H. Kitai
- Abstract
Loading... -
+
P2.10-018 - Drug selection in non-small cell lung cancer patients: perspective of Korean physician
09:30 - 09:30 | Author(s): C. Son
- Abstract
Loading... -
+
P2.10-019 - A prospective cohort study of non-squamous non-small cell lung cancer patients treated with bevacizumab
09:30 - 09:30 | Author(s): K. Soejima
- Abstract
Loading... -
+
P2.10-020 - Dose escalation and pharmacokinetic study of carboplatin and pemetrexed for elderly patients with advanced non-squamous, non-small-cell lung cancer: Kumamoto Thoracic Oncology Study Group Trial 1002
09:30 - 09:30 | Author(s): S. Saeki
- Abstract
Loading... -
+
P2.10-021 - The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor.
09:30 - 09:30 | Author(s): R. Ko
- Abstract
Loading... -
+
P2.10-022 - Prospective observational cohort study of second-line chemotherapy administration after first-line platinum-based chemotherapy for patients with advanced NSCLC in Japan (SAPPHIRE study)
09:30 - 09:30 | Author(s): Y. Goto
- Abstract
Loading... -
+
P2.10-023 - Feasibility study of pemetrexed (PEM) plus bevacizumab (BV) as the first-line treatment for elderly advanced or recurrent non-squamous (non-Sq) non-small cell lung cancer (NSCLC): TORG1015.
09:30 - 09:30 | Author(s): T. Kozuki
- Abstract
Loading... -
+
P2.10-024 - Usefulness of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy.
09:30 - 09:30 | Author(s): K. Suzuki
- Abstract
Loading... -
+
P2.10-025 - Weekly paclitaxel (wPCT) for pre-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): a single institution experience in the daily clinical practice.
09:30 - 09:30 | Author(s): O. Caffo
- Abstract
Loading... -
+
P2.10-026 - Final results of EGFR mutation reanalysis and KRAS mutation screening by Scorpion ARMS method: Phase II Study of Erlotinib for EGFR wild type Non-small cell Lung Cancer Patients. Central Japan Lung Study Group (CJLSG) 0903 trial.
09:30 - 09:30 | Author(s): E. Maruyama
- Abstract
Loading... -
+
P2.10-027 - Mutation of epidermal growth factor receptor gene and efficacy of gefitinib in squamous cell carcinoma of lung
09:30 - 09:30 | Author(s): T. Miwa
- Abstract
Loading... -
+
P2.10-028 - Efficacy and safety of erlotinib in elderly versus non-elderly patients: analysis of the POLARSTAR study of 9,909 Japanese non-small cell lung cancer (NSCLC) patients treated with erlotinib.
09:30 - 09:30 | Author(s): T. Koba
- Abstract
Loading... -
+
P2.10-029 - Educating community health professionals about lung cancer: A pilot evaluation of a web-based educational tool
09:30 - 09:30 | Author(s): P.M. Ellis
- Abstract
Loading... -
+
P2.10-030 - Eastern Cooperative Oncology Group (ECOG) score: Agreement between non-small-cell lung cancer (NSCLC) patients and their oncologists and clinical implications
09:30 - 09:30 | Author(s): M.A. Malalasekera
- Abstract
Loading... -
+
P2.10-031 - Chinese randomized phase II trial of customized chemotherapy based on BRCA1-RAP80 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) (ChiCTR-TRC-12001860/BREC-CHINA)
09:30 - 09:30 | Author(s): J. Wei
- Abstract
Loading... -
+
P2.10-032 - Palliative chemotherapy of lung cancer in elderly : single center experiences
09:30 - 09:30 | Author(s): J. Jo
- Abstract
Loading... -
+
P2.10-033 - Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Iwasaku
- Abstract
Loading... -
+
P2.10-034 - Is Second Line Systemic Chemotherapy Beneficial in Patients with Non-Small Cell Lung Cancer (NSCLC)? : A Multicenter Data Evaluation of Anatolian Society of Medical Oncology (ASMO)
09:30 - 09:30 | Author(s): H. Odabas
- Abstract
Loading... -
+
P2.10-035 - EGFR mutation (m) status in serum only to treat Non Small Cell Lung Cancer (NSCLC) patients (p)
09:30 - 09:30 | Author(s): E. Carcereny
- Abstract
Loading... -
+
P2.10-036 - Overall Survival and Hospitalization Rates in Medicare Patients Diagnosed with Advanced NSCLC Treated With Bevacizumab- Paclitaxel-Carboplatin vs Paclitaxel-Carboplatin: A Retrospective Cohort Study
09:30 - 09:30 | Author(s): C.J. Langer
- Abstract
Loading... -
+
P2.10-037 - Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after completing at least 4 cycles of pemetrexed plus cisplatin induction treatment: a cross-trial analysis of two phase III trials
09:30 - 09:30 | Author(s): G.V. Scagliotti
- Abstract
Loading... -
+
P2.10-038 - nab-Paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC): analysis of predictive factors
09:30 - 09:30 | Author(s): V. Hirsh
- Abstract
Loading... -
+
P2.10-039 - Outcomes of first line bevacizumab-based chemotherapy for NSCLC relative to the medications used to control hypertension (HTN).
09:30 - 09:30 | Author(s): H. Ali
- Abstract
Loading... -
+
P2.10-040 - Prognostic significance, accuracy and usefulness of oncologists' estimates of survival time for patients starting first-line chemotherapy for advanced non-small-cell lung cancer (ANSCLC)
09:30 - 09:30 | Author(s): B.E. Kiely
- Abstract
Loading... -
+
P2.10-041 - Optimising regulatory T cell (Treg) depletion in combination with chemotherapy for enhanced anti-tumour immunity
09:30 - 09:30 | Author(s): A.M. Cook
- Abstract
Loading... -
+
P2.10-042 - Lung cancer among Swedish and imigrants. Incidens, histopathology, treatment and survival.
09:30 - 09:30 | Author(s): H. Koyi
- Abstract
Loading... -
+
P2.10-043 - Phase II study of biweekly irinotecan plus bevacizumab in heavily treated advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A.F. Cardona
- Abstract
Loading... -
+
P2.10-044 - Impact of comorbidities on survival in elderly patients with non small cell lung cancer.
09:30 - 09:30 | Author(s): M. Kaya
- Abstract
Loading... -
+
P2.10-045 - Phase II study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) as first line therapy for non-squamous non small cell lung cancer (NSCLC) without EGFR Mutation. Central Japan Lung Study Group (CJLSG) 0909 trial.
09:30 - 09:30 | Author(s): Y. Goto
- Abstract
Loading... -
+
P2.10-046 - A phase I/II study of bexarotene with weekly paclitaxel and carboplatin for the treatment of patients with advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): J.D. Whyman
- Abstract
Loading... -
+
P2.10-047 - The three-drugs regimen CPBev (Cis-platinum, Pemetrexed and Bevacizumab) is very active when used as first-line therapy for locally advanced or metastatic adenocarcinoma of the lung: final results of a phase III trial.
09:30 - 09:30 | Author(s): R. Bordonaro
- Abstract
Loading... -
+
P2.10-048 - Therapeutic efficacy of gefitinib for postoperative recurrent cancer in patient with EGFR mutation
09:30 - 09:30 | Author(s): T. Oikawa
- Abstract
Loading... -
+
P2.10-049 - Lung and Bone Metastasis Are Associated With Different Response and Disease Control Rate of First-line Therapy in Patients With Adenocarcinoma of Lung.
09:30 - 09:30 | Author(s): C. Wu
- Abstract
Loading... -
+
P2.10-050 - Efficacy of Denosumab in patients with metastatic lung cancer with EGFR mutations
09:30 - 09:30 | Author(s): Y. Suido
- Abstract
Loading... -
+
P2.10-051 - The final analysis of prospective, feasibility study of S-1 and carboplatin combination chemotherapy for the patients with interstitial pneumonia (IP) and advanced non small cell lung cancer (NSCLC).
09:30 - 09:30 | Author(s): T. Kato
- Abstract
Loading... -
+
P2.10-052 - A Feasibility Study of Vinorelbine and Bevacizumab in Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): K. Kaburaki
- Abstract
Loading...
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-001 - ALK Genotyping via Liquid Based ThinPrep Slides Prepared from Fine Needle Aspirates in NSCLC
09:30 - 09:30 | Author(s): R.R. Tubbs
- Abstract
Loading... -
+
P2.11-002 - A Prospective, Open-labeled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation stage IIIA NSCLC Patients With EGFR 19 or 21 Exon Mutation (EVAN, ML28280, NCT01683175)
09:30 - 09:30 | Author(s): D. Yue
- Abstract
Loading... -
+
P2.11-003 - How to make the choice in the reuse of EGFR-TKI for advanced NSCLC patients who benefited from prior Gefitinib therapy: the original drug or switching to a second EGFR-TKI?
09:30 - 09:30 | Author(s): C. Tang
- Abstract
Loading... -
+
P2.11-004 - A Phase Ib, open label, dose escalation study of the safety and pharmacology of PI3-Kinase (PI3K) Inhibitor GDC 0941 in combination with either Paclitaxel (Pac) and Carboplatin (Carbo) with or without Bevacizumab (Bev), or Pemetrexed (Pem), Cisplatin (Cis), and Bev in patients with advanced Non–Small Cell Lung Cancer (NSCLC).
09:30 - 09:30 | Author(s): G.K. Dy
- Abstract
Loading... -
+
P2.11-005 - Randomized Phase II Study of Pemetrexed v. Pemetrexed/Bevacizumab v. Carboplatin/Pemetrexed/Bevacizumab in Patients with Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer and Poor Performance Status
09:30 - 09:30 | Author(s): R. Lilenbaum
- Abstract
Loading... -
+
P2.11-006 - Review of 10 Years of ASCO Abstracts for Non-Small Cell Lung Cancer (NSCLC) and the Impact of Molecular Biomarkers (MB) in Clinical Trial Selection Criteria
09:30 - 09:30 | Author(s): R.D. Gentzler
- Abstract
Loading... -
+
P2.11-007 - Relevance Between CEA Level and EGFR Mutation, Efficacy Of EGFR-TKI In Patients With Lung Adenocarcinoma
09:30 - 09:30 | Author(s): W.Y. Zhang
- Abstract
Loading... -
+
P2.11-008 - High Proportion of Unusual EGFR Mutations in an Australian Population of Non-Squamous NSCLC
09:30 - 09:30 | Author(s): H.W. Ainge-Allen
- Abstract
Loading... -
+
P2.11-009 - Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil.
09:30 - 09:30 | Author(s): R. Caires-Lima
- Abstract
Loading... -
+
P2.11-010 - Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior EGFR tyrosine kinase inhibitor (TKI) therapy.
09:30 - 09:30 | Author(s): D. Kim
- Abstract
Loading... -
+
P2.11-011 - A Phase Ib study of high-dose intermittent (HDI) afatinib in EGFR T790M mutation-positive non-small cell lung cancer patients with acquired resistance to reversible EGFR TKIs
09:30 - 09:30 | Author(s): D..R. Camidge
- Abstract
Loading... -
+
P2.11-012 - Phase Ia/Ib study of the anti-MET antibody onartuzumab (MetMAb) in patients with solid tumors or MET-positive lung cancer
09:30 - 09:30 | Author(s): H. Horinouchi
- Abstract
Loading... -
+
P2.11-013 - A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): D. Fennell
- Abstract
Loading... -
+
P2.11-014 - Biomarkers reduce clinical trial risk and the cost of drug development in non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): G. Lopes
- Abstract
Loading... -
+
P2.11-015 - Comparative effectiveness of gefitinib, erlotinib, afatinib and chemotherapy in the first line treatment of patients with advanced non small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations
09:30 - 09:30 | Author(s): G. Lopes
- Abstract
Loading... -
+
P2.11-016 - A Comparative Analysis of EGFR Mutation Status in Association with the Efficacy of TKI in Combination with WBRT/SRS/Surgery plus chemotherapy in Brain Metastasis from Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading... -
+
P2.11-017 - Icotinib in advanced lung adenocarcinoma patients pretreated with pemetrexed
09:30 - 09:30 | Author(s): Y. Zheng
- Abstract
Loading... -
+
P2.11-018 - EGFR mutations in NSCLC patients in Central Europe: the INSIGHT observational study
09:30 - 09:30 | Author(s): R. Pirker
- Abstract
Loading... -
+
P2.11-019 - Treatment strategies in patients with advanced EGFR mutation-positive NSCLC in Central Europe: Findings from the INSIGHT observational study
09:30 - 09:30 | Author(s): T. Cufer
- Abstract
Loading... -
+
P2.11-020 - Sorafenib in patients with RET fusion-positive non-small cell lung cancer
09:30 - 09:30 | Author(s): A. Horiike
- Abstract
Loading... -
+
P2.11-021 - Interim outcome analysis of phase II study of neoadjuvant bevacizumab plus pemetrexed and carboplatin in unresectable, locally advanced lung adenocarcinoma
09:30 - 09:30 | Author(s): N. Li
- Abstract
Loading... -
+
P2.11-022 - Phase IV, single-arm study of first-line gefitinib in Caucasian patients with epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small-cell lung cancer (NSCLC): post-hoc exploratory analyses of EGFR mutations in plasma-derived cfDNA samples
09:30 - 09:30 | Author(s): J. Douillard
- Abstract
Loading... -
+
P2.11-023 - BE-Positive: Gefitinib in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. A combined retrospective and prospective analysis from Italian patients.
09:30 - 09:30 | Author(s): S. Novello
- Abstract
Loading... -
+
P2.11-025 - Erlotinib versus Radiation Therapy for Brain Metastases in Patients with EGFR-Mutant Lung Adenocarcinoma
09:30 - 09:30 | Author(s): N.K. Gerber
- Abstract
Loading... -
+
P2.11-026 - RET Fusion-Positive Advanced Lung Cancers: Response to First-Line Chemotherapy and Survival in Comparison to ROS1 and ALK Fusion-Positive and EGFR- and KRAS-Mutant Lung Cancers
09:30 - 09:30 | Author(s): A. Drilon
- Abstract
Loading... -
+
P2.11-027 - The response of non-adenocarcinoma non-small-cell lung cancer patients with EGFR mutations to EGFR-TKI: A retrospective multicenter study (LOGIK 1104)
09:30 - 09:30 | Author(s): K. Sugio
- Abstract
Loading... -
+
P2.11-028 - Erlotinib salvage therapy in pulmonary adenocarcinoma patients who had disease progressed after previous EGFR-TKI treatment and platinum-based chemotherapies
09:30 - 09:30 | Author(s): W. Wu
- Abstract
Loading... -
+
P2.11-029 - EGFR-mutations and resulting treatment in a NSCLC population-based cohort in Central Sweden
09:30 - 09:30 | Author(s): M. Sandelin
- Abstract
Loading... -
+
P2.11-030 - Is there any predictor for clinical outcome in EGFR mutant
NSCLC patients treated with EGFR TKIs ?09:30 - 09:30 | Author(s): J.Y. Lee
- Abstract
Loading... -
+
P2.11-031 - Radiofrequency ablation of liver metastases may prolong the survival of pulmonary adenocarcinoma patients with liver metastasis
09:30 - 09:30 | Author(s): S. Tseng
- Abstract
Loading... -
+
P2.11-032 - Patient Report of Dacomitinib (PF-00299804)-Associated Symptom and HRQoL Benefit in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): J.P. Doherty
- Abstract
Loading... -
+
P2.11-033 - ALK-EML4-testing in non-small cell lung cancer:
Experiences from Karolinska University Hospital in Sweden09:30 - 09:30 | Author(s): S. Mindus
- Abstract
Loading... -
+
P2.11-034 - Indirect comparisons of harm/benefit profile of EGFR tyrosine kinase inhibitors as first line treatment in EGFR mutated NSCLC patients: a systematic review and meta-analysis
09:30 - 09:30 | Author(s): E.R. Haspinger
- Abstract
Loading... -
+
P2.11-036 - Association Between Tumor EGFR Mutation and primary tumor location in Patients with Adenocarcinoma of the Lungs
09:30 - 09:30 | Author(s): C. Huang
- Abstract
Loading... -
+
P2.11-037 - EGFR Activating Mutation and Bone Metastasis Have Association With CNS Metastasis at Diagnosis in Patients with Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): K.H. Kim
- Abstract
Loading... -
+
P2.11-038 - Efficacy of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC): subpopulation response analysis in a phase 1 trial
09:30 - 09:30 | Author(s): S. Gettinger
- Abstract
Loading... -
+
P2.11-039 - Results from phase III trial of dendritic cell based vaccine immunotherapy in patients with -IIIA stage non-small-cell lung cancer
09:30 - 09:30 | Author(s): N. Khranovska
- Abstract
Loading... -
+
P2.11-040 - Phase 1 study of ipilimumab in combination with paclitaxel/carboplatin in patients with non-small cell lung cancer
09:30 - 09:30 | Author(s): H. Nokihara
- Abstract
Loading... -
+
P2.11-041 - Effect of treatment duration on incidence of adverse events (AEs) in a phase III study of crizotinib versus chemotherapy in advanced ALK-positive non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A.T. Shaw
- Abstract
Loading... -
+
P2.11-042 - Acid suppression therapy impairs Erlotinib efficacy in Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M.P. Chu
- Abstract
Loading... -
+
P2.11-043 - Analysis of clinicopathological features for Chinese patients with advanced non-small cell lung cancer harboring EML4-ALK fusion genes
09:30 - 09:30 | Author(s): Y. Shi
- Abstract
Loading... -
+
P2.11-044 - Phase IB study to evaluate the efficacy and tolerability of Olaparib (AZD2281) plus Gefitinib in patients (P) with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced Non-Small Cell Lung Cancer (NSCLC) patients (P). (NCT=1513174/GECP-GOAL)
09:30 - 09:30 | Author(s): R. Garcia Campelo
- Abstract
Loading... -
+
P2.11-045 - TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
09:30 - 09:30 | Author(s): L. Nogova
- Abstract
Loading... -
+
P2.11-046 - A Novel Approach to Increase the Efficiency of Survival-Endpoint
Phase II Trials.09:30 - 09:30 | Author(s): G.R. Simon
- Abstract
Loading... -
+
P2.11-047 - Sequential treatment with erlotinib and pemetrexed in pretreated patients with lung adenocarcinoma.
09:30 - 09:30 | Author(s): O. Fiala
- Abstract
Loading... -
+
P2.11-048 - Nutritional status, body surface and sarcopenia are associated to dose reduction and severe gastrointestinal toxicity related to afatinib in patients with advanced NSCLC
09:30 - 09:30 | Author(s): O. Arrieta
- Abstract
Loading...
-
+
P2.12 - Poster Session 2 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 23
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.12-001 - Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutation (NCT01217619, EASTERN): study update
09:30 - 09:30 | Author(s): B. Han
- Abstract
Loading... -
+
P2.12-002 - Clinical characteristics and prognosis of lung adenocarcinoma driver mutations from Chinese population
09:30 - 09:30 | Author(s): Y. Dong
- Abstract
Loading... -
+
P2.12-003 - Postoperative recurrence and the personalized postoperative surveillance for resected lung cancer patients
09:30 - 09:30 | Author(s): S. Shiono
- Abstract
Loading... -
+
P2.12-004 - Percutaneous cryoablation for the treatment of inoperable stage I non-small cell lung cancer: mid-term outcome
09:30 - 09:30 | Author(s): Y. Yamauchi
- Abstract
Loading... -
+
P2.12-005 - Results of radical treatment of non-small cell lung cancer patients with a single synchronous metastasis
09:30 - 09:30 | Author(s): M. Kwint
- Abstract
Loading... -
+
P2.12-006 - Factors impacting the management of solid lung tumors by percutaneous radiofrequency ablation in non-surgical patients
09:30 - 09:30 | Author(s): P. Andrew
- Abstract
Loading... -
+
P2.12-007 - PET/CT Findings of Adenocarcinoma Patients
09:30 - 09:30 | Author(s): F. Kutluhan
- Abstract
Loading... -
+
P2.12-008 - Do PET/CT Findings Predict Clinical Staging in NSCLC ?
09:30 - 09:30 | Author(s): F. Kutluhan
- Abstract
Loading... -
+
P2.12-009 - Adjuvant chemotherapy with oral vinorelbine used in doublet with carboplatin in non-small cell lung cancer after radical resection - tolerability and short term survival.
09:30 - 09:30 | Author(s): V. Kolek
- Abstract
Loading... -
+
P2.12-010 - Does presence of chronic obstructive pulmonary disease (COPD) influence clinical behavior in patients with early stage non-small cell lung cancer (ES-NSCLC)?
09:30 - 09:30 | Author(s): S. Yamamoto
- Abstract
Loading... -
+
P2.12-011 - Pre-Radiotherapy PET SUV Maximum Predicts for Overall Survival in Patients with Early-Stage NSCLC Treated with Stereotactic Body Radiation Therapy
09:30 - 09:30 | Author(s): B.R. Mancini
- Abstract
Loading... -
+
P2.12-012 - Prognostic impact of visceral pleural invasion in resected tumors of non-small cell lung cancer
09:30 - 09:30 | Author(s): K. Sugio
- Abstract
Loading... -
+
P2.12-013 - Patterns of recurrence following surgical resection of stage I-III non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): H. Wong
- Abstract
Loading... -
+
P2.12-014 - Brain metastases following surgical resection of stage I-III non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): B. Zhang
- Abstract
Loading... -
+
P2.12-015 - Investigation of the FDG PET-derived Total Glycolytic Activity (TGA) as Prognostic Tool in Patients with Early Stage Resected Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Werner-Wasik
- Abstract
Loading... -
+
P2.12-016 - Predict foctors of lymphatics metastasis or early distant and regional failure after complete resection in cT1 lung adenocarcinoma
09:30 - 09:30 | Author(s): X. Hong
- Abstract
Loading... -
+
P2.12-017 - Clinical Impact of Dynamic Contrast-Enhanced CT in Stage IA Non-Small Cell Lung Cancer: Net Enhancement is an Independent Predictor of Recurrence.
09:30 - 09:30 | Author(s): E.Y. Kim
- Abstract
Loading... -
+
P2.12-018 - Brain metastases as a first site of recurrence in surgically resected non-small-cell lung cancer
09:30 - 09:30 | Author(s): W.J. Chang
- Abstract
Loading... -
+
P2.12-019 - Compliance, toxicity and successfull goals in adjuvant setting. Results from Two Referal Centers in South America.
09:30 - 09:30 | Author(s): E.N. Olguin
- Abstract
Loading... -
+
P2.12-020 - The Impact of Adjuvant Therapy in Resected Patients with Early Stage Non-Small Cell Lung Carcinoma: The ERCC1 and EGFR Expressions are Associated with Survival.
09:30 - 09:30 | Author(s): A. Aynaci
- Abstract
Loading... -
+
P2.12-021 - Selective mediastinal lymph node dissection for cN0 non-small cell lung cancer
09:30 - 09:30 | Author(s): T. Ishizumi
- Abstract
Loading... -
+
P2.12-022 - A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cance
09:30 - 09:30 | Author(s): M. Tsuboi
- Abstract
Loading... -
+
P2.12-023 - Pre-treatment 18FDG-PET SUVmax As A Predictor of Distant Metastasis in Early Stage NSCLC Treated with Definitive Radiotherapy
09:30 - 09:30 | Author(s): V.J. Nair
- Abstract
Loading...
-
+
P2.13 - Poster Session 2 - SCLC
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 7
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.13-001 - Additive first-line chemotherapies improve progression-free survival for combined small cell lung cancer in a phase II randomized trial.
09:30 - 09:30 | Author(s): J. Zhang
- Abstract
Loading... -
+
P2.13-002 - Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC)
09:30 - 09:30 | Author(s): A.A. Chiappori
- Abstract
Loading... -
+
P2.13-003 - Prognostic factors for extensive stage small cell lung cancer.
09:30 - 09:30 | Author(s): C. Son
- Abstract
Loading... -
+
P2.13-004 - Lithium as a neuroprotective agent in patients undergoing prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC): the TULIP study
09:30 - 09:30 | Author(s): M. Khasraw
- Abstract
Loading... -
+
P2.13-005 - Palonosetron (Aloxi®) effectively prevents nausea and emesis in SCLC patients receiving platinum-based three days regimen.
09:30 - 09:30 | Author(s): I. Gkiozos
- Abstract
Loading... -
+
P2.13-006 - A Phase IIa study of HA-Irinotecan, a CD44-targeted formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on cancer stem-like cells.
09:30 - 09:30 | Author(s): M. Alamgeer
- Abstract
Loading... -
+
P2.13-007 - Impact of age on treatment and survival in patients with small cell lung cancer.
09:30 - 09:30 | Author(s): H.S. Takhar
- Abstract
Loading...
-
+
P2.14 - Poster Session 2 - Mesothelioma
- Type: Poster Session
- Track: Mesothelioma
- Presentations: 15
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.14-001 - Trimodality treatment of malignant pleural Mesothelioma (MPM). A review of 53 consecutive patients with malignant pleural Mesothelioma, period 10-years January 2002- December 2012.
09:30 - 09:30 | Author(s): F. Gradica
- Abstract
Loading... -
+
P2.14-002 - Validation of the CALGB and EORTC Prognostic Models for Mesothelioma Based on Multiple CALGB Trials (Alliance)
09:30 - 09:30 | Author(s): H. Pang
- Abstract
Loading... -
+
P2.14-003 - Phase I and pharmacokinetic study of amatuximab, a novel chimeric antibody to mesothelin, in patients with advanced solid tumors
09:30 - 09:30 | Author(s): T. Kurata
- Abstract
Loading... -
+
P2.14-004 - EORTC and CALGB prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in unselected patients with newly diagnosed malignant mesothelioma
09:30 - 09:30 | Author(s): T. Meniawy
- Abstract
Loading... -
+
P2.14-005 - Assessment of postoperative complications after the first all Japan multi-institutional trial of induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma
09:30 - 09:30 | Author(s): N. Usami
- Abstract
Loading... -
+
P2.14-006 - Is Pleurectomy-Decortication a Viable Management Option in the Treatment of Malignant Pleural Mesothelioma?
09:30 - 09:30 | Author(s): H. Wilson
- Abstract
Loading... -
+
P2.14-007 - Global patterns in the incidence of malignant mesothelioma, 1988-2002, using data published by the International Agency for Research on Cancer (IARC)
09:30 - 09:30 | Author(s): M.J. Soeberg
- Abstract
Loading... -
+
P2.14-008 - Effect of Aquaporin 1 Modulation in Malignant Pleural Mesothelioma: Inhibition of Cell Proliferation and Colony Formation in vitro and Tumour Growth in vivo using a Heterotopic Mouse Model
09:30 - 09:30 | Author(s): J. Driml
- Abstract
Loading... -
+
P2.14-009 - Novel Clinical Assessment of Malignant Pleural Mesothelioma
09:30 - 09:30 | Author(s): R.R. Gill
- Abstract
Loading... -
+
P2.14-010 - Intrapleural Perfusion Hyperthermo-Chemotherapy with Cisplatin in Patients with Malignant Pleural Mesothelioma.
09:30 - 09:30 | Author(s): H. Sakaguchi
- Abstract
Loading... -
+
P2.14-011 - MesobanK: A UK based bioresource for malignant pleural mesothelioma
09:30 - 09:30 | Author(s): R.C. Rintoul
- Abstract
Loading... -
+
P2.14-012 - Oncolytic herpes virus therapy for mesothelioma- a Phase I study of intrapleural oncolytic virus HSV1716 (NCT01721018)
09:30 - 09:30 | Author(s): P. Woll
- Abstract
Loading... -
+
P2.14-013 - A randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma (MPM) expressing BRAC1 - VIM trial
09:30 - 09:30 | Author(s): D. Fennell
- Abstract
Loading... -
+
P2.14-014 - A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of VS-6063 as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum therapy
09:30 - 09:30 | Author(s): M. Keegan
- Abstract
Loading... -
+
P2.14-015 - A randomized, double-blind study comparing tremelimumab to placebo in second and third line treatment of subjects with unresectable pleural or peritoneal mesothelioma
09:30 - 09:30 | Author(s): H.L. Kindler
- Abstract
Loading...
-
+
P2.15 - Poster Session 2 - Thymoma
- Type: Poster Session
- Track: Thymoma & Other Thoracic Malignancies
- Presentations: 8
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.15-001 - Predictors of long-term survivals in patients with Masaoka stage III thymomas
09:30 - 09:30 | Author(s): Q. Feng
- Abstract
Loading... -
+
P2.15-002 - Patterns and Predictors of Recurrence after radical resection of Thymoma
09:30 - 09:30 | Author(s): C. Xu
- Abstract
Loading... -
+
P2.15-003 - Gli1, Notch1 and CTNNB1 Expression by Automated Quantitative Immunofluorescence (AQUA) in a Thymic Malignancy Tissue Microarray (TMA)
09:30 - 09:30 | Author(s): J.W. Riess
- Abstract
Loading... -
+
P2.15-004 - Management of primary tumours of the Thymus and usefulness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET).
09:30 - 09:30 | Author(s): S.D. Moraitis
- Abstract
Loading... -
+
P2.15-005 - Long-term survival after the multimodal treatment of thymic carcinomas: A single center experiences in 90 cases.
09:30 - 09:30 | Author(s): G.D. Lee
- Abstract
Loading... -
+
P2.15-006 - Retrospective study on the efficacy of multidisciplinary therapy for thymic cancers
09:30 - 09:30 | Author(s): M. Hashimoto
- Abstract
Loading... -
+
P2.15-007 - Digital Microscopy Reproducibility Study of Thymic Epithelial Neoplasms
09:30 - 09:30 | Author(s): A.L. Moreira
- Abstract
Loading... -
+
P2.15-008 - Comparison of outcomes after extended thymectomy for myasthenia gravis by presence of thymoma
09:30 - 09:30 | Author(s): S. Kadoma
- Abstract
Loading...
-
+
P2.16 - Poster Session 2 - Other Thoracic Malignancies
- Type: Poster Session
- Track: Thymoma & Other Thoracic Malignancies
- Presentations: 4
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.16-001 - Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer
09:30 - 09:30 | Author(s): K. Shimizu
- Abstract
Loading... -
+
P2.16-002 - Long-term Treatment Results in Soft Tissue Sarcomas of The Thoracic Wall Treated by Pre-or-Postoperative Radiotherapy in a Multidisciplinary Approach-
Results of the CTF Sarcoma Group09:30 - 09:30 | Author(s): H.F. Dincbas
- Abstract
Loading... -
+
P2.16-003 - The efficacy of VATS versus open thoracotomy: a systematic review
09:30 - 09:30 | Author(s): M.Y. Cheang
- Abstract
Loading... -
+
P2.16-004 - Medical management of pulmonary carcinoid tumors
09:30 - 09:30 | Author(s): C. Chong
- Abstract
Loading...
-
+
P2.17 - Poster Session 2 - Bronchoscopy, Endoscopy
- Type: Poster Session
- Track: Pulmonology + Endoscopy/Pulmonary
- Presentations: 9
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.17-001 - A combination use of multi-guided devices in the basis of the obtained data from virtual bronchoscopic navigation LungPoint system using thin video-bronchoscope for diagnosing small (≤ 30 mm) peripheral pulmonary lesions suspected lung cancer
09:30 - 09:30 | Author(s): M. Misawa
- Abstract
Loading... -
+
P2.17-002 - Retrospective study of 5-year experience with endobronchial cryobiopsy in Republic of Estonia.
09:30 - 09:30 | Author(s): T. Vanakesa
- Abstract
Loading... -
+
P2.17-003 - Early experience of endobronchial ultrasound-miniprobe (EBUS-MP) for investigation of peripheral pulmonary mass lesions
09:30 - 09:30 | Author(s): J.F. Tiernan
- Abstract
Loading... -
+
P2.17-004 - Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) Investigation of Mediastinal Lymphadenopathy of Unknown Aetiology
09:30 - 09:30 | Author(s): P.A. Reid
- Abstract
Loading... -
+
P2.17-005 - Conventional vs ultrathin bronchoscopy in the diagnosis of solitary pulmonary nodules (SPN).
09:30 - 09:30 | Author(s): J.A. Botero Zaccour
- Abstract
Loading... -
+
P2.17-006 - Long term outcome of initial bronchoscopic treatment strategy in patients with bronchial carcinoids
09:30 - 09:30 | Author(s): H.A.P. Brokx
- Abstract
Loading... -
+
P2.17-007 - Misclassification of mediastinal lymph nodes by endobronchial ultrasound (EBUS)
09:30 - 09:30 | Author(s): C.S. Leem
- Abstract
Loading... -
+
P2.17-008 - A new procedure for sampling fine needle aspirations enables isolation of high quality mRNA
09:30 - 09:30 | Author(s): B.S. Paulsen
- Abstract
Loading... -
+
P2.17-009 - How to perform EBUS TBNA and when is it sufficient ?
09:30 - 09:30 | Author(s): M. Krasnik
- Abstract
Loading...
first
prev
